• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDepartmentThis CollectionBy Issue DateAuthorsTitlesSubjectsDepartment

    My Account

    LoginRegister

    Development of Optical Metabolic Imaging for Pancreatic and Breast Cancer Precision Medicine

    Sharick, Joseph Thomas
    : https://etd.library.vanderbilt.edu/etd-03112019-230705
    http://hdl.handle.net/1803/15371
    : 2019-03-12

    Abstract

    There are no reliable methods to determine how an individual breast or pancreatic cancer patient will respond to a particular treatment option. Patient-derived tumor organoids offer the ability to screen drugs directly on a patient’s cells in vitro to determine drug effectiveness, however we currently lack the tools to evaluate distinct cellular subpopulations of response within these organoids. This cellular heterogeneity is a major cause of cancer treatment failure, as drug-resistant cell subpopulations continue to proliferate even when a majority of the tumor appears to be drug-responsive. Therefore, technology to assess heterogeneous responses to cancer treatments in patient organoids is needed. In this dissertation, optical metabolic imaging (OMI) was developed for measuring drug-induced changes in metabolic heterogeneity in pancreatic and breast cancer organoids. OMI leverages the intrinsic autofluorescence intensities and lifetimes of the metabolic coenzymes NAD(P)H and FAD to quantify the metabolic state of individual cells. First, a novel biochemical interpretation for changes in the fluorescence lifetime of NAD(P)H was established, connecting OMI measurements with shifts in flux through specific metabolic pathways which may contribute to anti-cancer drug resistance. Next, OMI was performed in vivo in an immunocompetent mouse model of breast cancer, and also in organoids derived from the same tumor model, to demonstrate that metabolic heterogeneity in tumor-derived organoids accurately recapitulates that of the original tumor. Finally, OMI of cellular heterogeneity in organoids was evaluated as a predictor of clinical treatment response for pancreatic cancer. Organoids were generated from fresh patient tissue samples acquired during surgery and treated with the same drugs as the patient’s prescribed adjuvant treatment. Early changes in metabolic heterogeneity in organoids agreed with long-term patient therapeutic response. OMI could serve as a sensitive, high-throughput tool to identify optimal therapies for individual pancreatic cancer patients, and to develop new effective therapies that address cellular heterogeneity in breast and pancreatic cancer.
    Show full item record

    Files in this item

    Icon
    Name:
    Sharick.pdf
    Size:
    12.24Mb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Electronic Theses and Dissertations

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy